Sharemaestro company-news research for BioNTech SE (BNTX), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest BNTX news and sentiment
BioNTech SE
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
53 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone51/100
→
Published 30-day score50/100
Latest source headline
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
24/7 Wall St. · 09 Oct 2026 15:48
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
53 current stories are mapped specifically to BNTX.
The score uses 9 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.330.
Confidence is 25/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
25/100
Confidencethin evidence
97%/100
Company news53 company stories
85/100
Story agreement15/100 difference
News history
Daily score and story count over 30 days
11 Sep26 Sep10 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence7
0.33 after freshness weightingSource breadth100
9 independent publishersCompany relevance97
share tied directly to this companyFreshness40
recency-weighted evidenceAgreement85
how closely stories agreePublisher mix81
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 96.96+0.1%
02 Oct 202647USD 96.9-1.6%
25 Sep 202652USD 98.52+2.6%
18 Sep 202651USD 96.06-0.7%
11 Sep 202649USD 96.73-6.8%
04 Sep 202649USD 103.76+1.7%
28 Aug 202649USD 102.075-12.4%
21 Aug 202652USD 116.57+25.2%
Provisional evidence
News subjects
What is shaping the score
Market update4528 stories · 53%
Earnings5112 stories · 23%
Analyst action575 stories · 9%
Regulatory and legal515 stories · 9%
Guidance523 stories · 6%
Source mix
Where the evidence comes from
Stock Titan417 stories · 13%
24/7 Wall St.506 stories · 11%
AD HOC NEWS455 stories · 9%
Simply Wall St.494 stories · 8%
The Motley Fool513 stories · 6%
Yahoo! Finance Canada503 stories · 6%
The Globe and Mail712 stories · 4%
Recurring subjects
Subjects appearing most often
Life Sciences33Financial Markets24Earnings20Biotech11Clinical Trials8Oncology7Pharma5Finance5Lung Cancer3Valuation2
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
30 Jul50 neutral10 Oct 20:01
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 10 Oct 20:01 | 50 | +0 | 25/100 (-2) | 53 (0) | Provisional |
| 09 Oct 23:59 | 50 | +0 | 27/100 (-3) | 53 (+2) | Provisional |
| 08 Oct 23:59 | 50 | +0 | 30/100 (-4) | 51 (-2) | Provisional |
| 07 Oct 23:59 | 50 | +2 | 34/100 (+3) | 53 (+3) | Provisional |
| 06 Oct 23:59 | 48 | -1 | 31/100 (0) | 50 (0) | Provisional |
| 05 Oct 23:59 | 49 | +2 | 31/100 (0) | 50 (+2) | Provisional |
| 03 Oct 23:59 | 47 | +0 | 31/100 (-3) | 48 (+2) | Provisional |
| 02 Oct 23:59 | 47 | +0 | 34/100 (0) | 46 (0) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 53 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action4 stories
10.7%28.1%
Market update8 stories
35.6%0.0%
Earnings2 stories
0.0%13.2%
Guidance1 story
0.0%9.3%
Regulatory and legal1 story
0.0%3.2%
Each side uses the same scale: 0–35.6% of the retained directional evidence.
Where the influence comes from
26.5%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
—Unscored
EarningsNot used in direction
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults a…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) announced on August 27 that the U.S. FDA has approved the supplemental Biologics License Application for their 2026–2027 COVID-19 vaccine formula, COMIRNATY XFG. The updated formula targets the XFG variant and is authorized for adults aged 65 and older, as well as individuals aged 5 to 64 with high-risk underlying conditions. Based on clinical, real-world, and manufacturing data demonstrating strong immune responses against circulating strains, the approval aligns with FDA strain guidance for fall 2026. You May Also Want to Look At: Pfizer (
- Published
- 24 Sep 2026 20:27
- News subject
- Earnings
- Why this score
- Contract or approval won
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 3 consolidated
Balance SheetCovid 19 VaccineFda ApprovalPharma
40/100 tone
BioNTech CEO Ugur Sahin sold 69,000 ordinary shares of BNTX on September 23 and 24, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026. The sales totaled approximately $6.84 million, with shares sold at prices of $99.4027 and $98.9913, respectively. Sahin still indirectly …
0.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
BioNTech CEO Ugur Sahin sold 69,000 ordinary shares of BNTX on September 23 and 24, 2026, under a Rule 10b5-1 trading plan established on June 3, 2026. The sales totaled approximately $6.84 million, with shares sold at prices of $99.4027 and $98.9913, respectively. Sahin still indirectly holds over 39 million shares through Medine GmbH, where he is the sole shareholder.
- Published
- 24 Sep 2026 20:53
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 0.2% of directional evidence · 16.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceLife Sciences
—Unscored
Market updateNot used in direction
BNTX Stock Price and Chart — NASDAQ:BNTX
This article provides an overview of BioNTech SE (NASDAQ: BNTX) stock, including its price performance, key facts, and financial statistics. Recent developments include potential job cuts and site closures, ongoing patent litigation with Bayer CropScience, and a revised price target from …
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides an overview of BioNTech SE (NASDAQ: BNTX) stock, including its price performance, key facts, and financial statistics. Recent developments include potential job cuts and site closures, ongoing patent litigation with Bayer CropScience, and a revised price target from Citi. The company continues to be active in mRNA technology beyond COVID-19, with a focus on oncology and other therapies.
- Published
- 24 Sep 2026 13:00
- News subject
- Market update
- Why this score
- Operational disruption
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
71/100 tone
Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE (BNTX) with a price target of $136.00. This rating aligns with Morgan Stanley's Buy rating, though BMO Capital has a Hold rating on the stock. BioNTech SE reported a quarterly revenue of $105.6 million and a GAAP…
1.6% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Canaccord Genuity analyst John Newman maintained a Buy rating on BioNTech SE (BNTX) with a price target of $136.00. This rating aligns with Morgan Stanley's Buy rating, though BMO Capital has a Hold rating on the stock. BioNTech SE reported a quarterly revenue of $105.6 million and a GAAP net loss of $820.8 million for the quarter ending June 30.
- Published
- 24 Sep 2026 12:53
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 1.6% of directional evidence · 16.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
57/100 tone
BioNTech stock rose 2.0 percent after the close on September 22, 2026, reaching USD 100.42 in Tuesday morning trading on the Nasdaq. This increase followed a prior Nasdaq close of USD 97.71 on September 21, and the company had gained 5 percent year-to-date. The outlook also noted that BMO…
9.4% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BioNTech stock rose 2.0 percent after the close on September 22, 2026, reaching USD 100.42 in Tuesday morning trading on the Nasdaq. This increase followed a prior Nasdaq close of USD 97.71 on September 21, and the company had gained 5 percent year-to-date. The outlook also noted that BMO had recently lowered its 12-month target for BioNTech shares from USD 128 to USD 105.
- Published
- 22 Sep 2026 22:30
- News subject
- Guidance
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 9.4% of directional evidence · 18.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
40/100 tone
BioNTech CEO Ugur Sahin sold 79,000 Ordinary Shares of BNTX on September 21-22, 2026, through a Rule 10b5-1 trading plan. Despite these sales, Sahin retains a significant indirect stake of 39,218,111 Ordinary Shares held via Medine GmbH, for which he is the sole shareholder. The transacti…
<0.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
BioNTech CEO Ugur Sahin sold 79,000 Ordinary Shares of BNTX on September 21-22, 2026, through a Rule 10b5-1 trading plan. Despite these sales, Sahin retains a significant indirect stake of 39,218,111 Ordinary Shares held via Medine GmbH, for which he is the sole shareholder. The transactions were executed at prices of $100.7182 and $97.8097 per share.
- Published
- 22 Sep 2026 20:54
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- <0.1% of directional evidence · 18.0d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsLife Sciences
—Unscored
GuidanceNot used in direction
BioNTech price tries to regain footing - Forecast today - 23-09-2026
BioNTech SE (BNTX) showed an advance in recent intraday trading, finding support at its 50-day Simple Moving Average and exhibiting fresh bullish signals from momentum indicators in oversold territory. The stock is maintaining a short-term uptrend, following an ascending trendline. The ou…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech SE (BNTX) showed an advance in recent intraday trading, finding support at its 50-day Simple Moving Average and exhibiting fresh bullish signals from momentum indicators in oversold territory. The stock is maintaining a short-term uptrend, following an ascending trendline. The outlook remains bullish as long as support at $95.30 holds, with an expected target of $105.50 for its first resistance level.
- Published
- 22 Sep 2026 12:32
- News subject
- Guidance
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Analyst actionNot used in direction
BioNTech Stock Recently Got Downgraded. But Is Wall Street Underestimating Its Cancer Pipeline?
BMO Capital Markets downgraded BioNTech (BNTX) from "outperform" to "market perform" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that Bi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BMO Capital Markets downgraded BioNTech (BNTX) from "outperform" to "market perform" and lowered its price target due to waning COVID-19 vaccine demand and a setback in its colorectal cancer vaccine trial. Despite these challenges and a revised revenue forecast, the article argues that BioNTech's extensive oncology pipeline, with over 25 Phase 2 and Phase 3 clinical studies, is being underestimated by Wall Street. The company also holds significant cash reserves, suggesting that investors can acquire a robust pipeline at a perceived value.
- Published
- 22 Sep 2026 09:54
- News subject
- Analyst action
- Why this score
- Analyst downgrade
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
BiotechCancerClinical TrialsEarningsFinancial MarketsLife Sciences
61/100 tone
BioNTech SE (BNTX), a German biotechnology firm known for its mRNA vaccine, presents a potential 23% upside despite current financial challenges including a negative P/E ratio and revenue growth. The company is strategically diversifying its pipeline into oncology and other infectious dis…
4.6% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BioNTech SE (BNTX), a German biotechnology firm known for its mRNA vaccine, presents a potential 23% upside despite current financial challenges including a negative P/E ratio and revenue growth. The company is strategically diversifying its pipeline into oncology and other infectious diseases. While financial metrics suggest caution, analyst ratings remain optimistic, highlighting a balance between innovative potential and financial health for investors.
- Published
- 22 Sep 2026 05:54
- News subject
- Earnings
- Why this score
- Operating growth
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 38/100
- 30-day weight
- 4.6% of directional evidence · 18.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher
Quick Read Moderna surged 9% to $168 after its Phase 3 melanoma vaccine study earned the ESMO congress's highest-profile Presidential Symposium slot on October 24. Merck gained just 1% and BioNTech 2%, signaling the market views this as a Moderna-specific re-rating, not a broad mRNA oncol…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Quick Read Moderna surged 9% to $168 after its Phase 3 melanoma vaccine study earned the ESMO congress's highest-profile Presidential Symposium slot on October 24. Merck gained just 1% and BioNTech 2%, signaling the market views this as a Moderna-specific re-rating, not a broad mRNA oncology validation. No new efficacy data was released Monday; the Presidential Symposium slot itself is the signal, as organizers reserve it for practice-changing datasets. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn't make the cut. Ente
- Published
- 21 Sep 2026 15:45
- News subject
- Market update
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
BiotechClinical TrialsModernaOncologyPrice TargetSplit
—Unscored
Market updateNot used in direction
BioNTech SE - American Depositary Shares (NQ: BNTX)
This article provides a brief overview of BioNTech SE (BNTX) stock performance, showing a price of 100.87 with a 2.87 (+2.93%) increase, as of 4:00 PM EDT, Sep 22, 2026. It lists various sections for investors to find more information, such as detailed quotes, charting, historical prices,…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a brief overview of BioNTech SE (BNTX) stock performance, showing a price of 100.87 with a 2.87 (+2.93%) increase, as of 4:00 PM EDT, Sep 22, 2026. It lists various sections for investors to find more information, such as detailed quotes, charting, historical prices, news, and research reports. The content primarily focuses on providing a framework for accessing financial data related to BioNTech SE.
- Published
- 19 Sep 2026 05:54
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Moderna Climbs 6% as Cancer Vaccine Trade Extends a 137% Month; BioNTech and Novavax Edge Higher
Quick Read Moderna surged 5% to $152.83, extending a stunning 137% one-month run fueled solely by its Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk. BioNTech edged up just 1% despite running a rival mRNA cancer vaccine program, signaling markets are backing Mod…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Quick Read Moderna surged 5% to $152.83, extending a stunning 137% one-month run fueled solely by its Phase 2b melanoma vaccine data showing a 49% reduction in recurrence risk. BioNTech edged up just 1% despite running a rival mRNA cancer vaccine program, signaling markets are backing Moderna's specific asset, not the broader platform. A Phase 3 adjuvant melanoma interim analysis expected in late 2026 is the next swing factor, with Madrid's October oncology congress as the nearest public data window. Read More: Avoid these 13 retirement mistakes before they derail your future (sponsor) Cancer
- Published
- 17 Sep 2026 13:50
- News subject
- Market update
- Why this score
- Large positive market reaction, Positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 23.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
BiotechCancer VaccineClinical TrialsEarningsGuidanceRevenue Growth
—Unscored
EarningsNot used in direction
Is BioNTech (BNTX) Too Pricey for Its Current Sales Base?
BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it traded several years ago, the issue is whether tod…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech has been in focus again after fresh clinical trial results, yet the long slide in the share price keeps pulling attention back to a simple question about what investors are paying for its sales. With the stock well below where it traded several years ago, the issue is whether today's valuation rests on a solid revenue base or on expectations that are hard to pin down. Over the past 5 years the share price has fallen 71.5%, which puts the spotlight firmly on whether the current valuation can still be explained by the company's sales profile. News that gotistobart nearly doubled median
- Published
- 16 Sep 2026 22:13
- News subject
- Earnings
- Why this score
- Missed expectations, Improving financial comparison
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 24.0d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
BiotechClinical TrialsOncologyShare PriceSplitValuation
57/100 tone
Regulatory and legal
BioNTech (BNTX) Posts Strong Lung Cancer Data, Is It A Bargain?
BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. At around US$96.69 per share, BioNTech has seen a…
3.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
BioNTech (NasdaqGS:BNTX) moved after fresh clinical news, as investors reacted to detailed Phase 3 data showing its investigational lung cancer therapy gotistobart nearly doubled median overall survival compared with standard chemotherapy. At around US$96.69 per share, BioNTech has seen a 30 day share price return of 3.87% and a 90 day share price return of 4.85%, while the 1 year total shareholder return declined 2.59% and the 5 year total shareholder return fell 71.40%. This suggests that short term momentum has picked up even as long term holders have experienced heavy losses. Scan beyond B
- Published
- 16 Sep 2026 19:08
- News subject
- Regulatory and legal
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Low · 30/100
- 30-day weight
- 3.2% of directional evidence · 24.1d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Clinical TrialsEarningsM AOncologyPharmaRevenue Growth
—Unscored
Regulatory and legalNot used in direction
BioNTech’s Lung Cancer Drug Shows Signs of a Major Breakthrough
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior imm…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need. The result builds on earlier Stage 1 data, where gotistobart red
- Published
- 15 Sep 2026 14:37
- News subject
- Regulatory and legal
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Balance SheetBiotechClinical TrialsLung CancerOncologyPharma
—Unscored
Market updateNot used in direction
BioNTech SE (BNTX) Gets a Buy from Morgan Stanley
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 15 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Why Is BioNTech Stock Gaining Monday?
On Monday, BioNTech SE(NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times compared to standard chemotherapy for a specific pa…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
On Monday, BioNTech SE(NASDAQ:BNTX) and OncoC4 Inc. released the first median overall survival results from stage 1 of their global PRESERVE-003 Phase 3 trial. The data indicate their investigational therapy nearly doubled survival times compared to standard chemotherapy for a specific patient population. Following the announcement, the stock jumped nearly 2%. Evaluating Gotistobart for Lung Cancer The study investigates gotistobart (BNT316 or ONC-392) for metastatic squamous non-small cell lung cancer (NSCLC). It focuses on patients whose cancer advanced despite prior immunotherapy and chemot
- Published
- 14 Sep 2026 14:35
- News subject
- Earnings
- Why this score
- Positive market reaction, Large positive market reaction
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.3d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
BiotechClinical TrialsLung CancerPharma
71/100 tone
Market update
BioNTech stock jumps on positive lung cancer trial data
BioNTech's shares jumped after the company announced positive clinical trial data for its experimental lung cancer drug, gotistobart. The drug nearly doubled the median overall survival rate in patients with squamous non-small cell lung cancer compared to standard chemotherapy. This data …
<0.1% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
BioNTech's shares jumped after the company announced positive clinical trial data for its experimental lung cancer drug, gotistobart. The drug nearly doubled the median overall survival rate in patients with squamous non-small cell lung cancer compared to standard chemotherapy. This data comes from an ongoing Phase 3 trial and was presented at a major lung cancer conference.
- Published
- 14 Sep 2026 12:37
- News subject
- Market update
- Why this score
- Positive market reaction
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- <0.1% of directional evidence · 26.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
BioNTech adds clinical weight to its oncology pivot at WCLC 2026
BioNTech presented new clinical data at the World Conference on Lung Cancer (WCLC) in Seoul, bolstering its oncology strategy beyond its mRNA platform. The anti-CTLA-4 antibody gotistobart showed significant survival benefits in previously treated NSCLC, while the bispecific antibody pumi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech presented new clinical data at the World Conference on Lung Cancer (WCLC) in Seoul, bolstering its oncology strategy beyond its mRNA platform. The anti-CTLA-4 antibody gotistobart showed significant survival benefits in previously treated NSCLC, while the bispecific antibody pumitamig demonstrated encouraging signals across tumor types and in combination with an ADC. These developments highlight BioNTech's pivot towards a diverse, combination-driven oncology portfolio.
- Published
- 14 Sep 2026 09:37
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
BioNTech SE Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year1 Gotistobart de…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech SE Gotistobart continues to show potential aschemotherapy-free monotherapy to reignite anti-tumor immunity in previously treated patients with squamous non-small cell lung cancer, where median survival with current standard of care treatments is less than one year1 Gotistobart demonstrated a median overall survival of 18.5 months compared to 10.0 months with standard-of-care chemotherapy in updated data from stage 1 of the PRESERVE-003 Phase 3 clinical trial, nearly doubling median survival in this patient population Findings are consistent with gotistobart's differentiated mechanism
- Published
- 14 Sep 2026 08:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.6d old
- Text assessed
- Stored article
- Duplicates
- 2 consolidated
Clinical TrialsImmunotherapyLung CancerPharma
—Unscored
Market updateNot used in direction
BioNTech says lung cancer drug candidate prolonged lives in trial
BioNTech announced that its drug candidate, gotistobart, significantly extended overall survival in patients with squamous non-small cell lung cancer whose disease had progressed despite prior immunotherapy and chemotherapy. Results from the PRESERVE-003 Phase 3 clinical trial showed that…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
BioNTech announced that its drug candidate, gotistobart, significantly extended overall survival in patients with squamous non-small cell lung cancer whose disease had progressed despite prior immunotherapy and chemotherapy. Results from the PRESERVE-003 Phase 3 clinical trial showed that gotistobart nearly doubled survival compared to standard-of-care chemotherapy. This marks a clinically meaningful benefit for a specific type of lung cancer.
- Published
- 14 Sep 2026 08:07
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 26.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life Sciences
—Unscored
Market updateNot used in direction
Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat
Quick Read Moderna surges 8% while cancer-vaccine partner Merck slips 0.3% and peer BioNTech gains just 0.5%, pointing to a Moderna-specific momentum or short-squeeze event. XBI falls 0.1% and SPY rises less than 1%, eliminating both sector tailwinds and broad market strength as drivers o…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Quick Read Moderna surges 8% while cancer-vaccine partner Merck slips 0.3% and peer BioNTech gains just 0.5%, pointing to a Moderna-specific momentum or short-squeeze event. XBI falls 0.1% and SPY rises less than 1%, eliminating both sector tailwinds and broad market strength as drivers of Moderna's rally. Already up 143% in a month on August's late-stage melanoma trial win, Moderna's latest jump has no new clinical, regulatory, or analyst trigger behind it. Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Merck didn't make the cut.
- Published
- 11 Sep 2026 15:56
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.2d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
BiotechCancer VaccineMomentumPrice Target
—Unscored
EarningsNot used in direction
BioNTech (BNTX) Stock Stays Rich On Sales As Revenue Looks Weaker
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 11 Sep 2026 10:29
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 29.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
BNTX news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 124 older BNTX headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to BNTX, but the headline and available text are not mainly about BioNTech SE. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of BNTX sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.